Brief: Dynavax Reports First Quarter 2023 Financial Results
May 2 (Reuters) - Dynavax Technologies Corp DVAX.O :
* DYNAVAX REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS
* REAFFIRMING HEPLISAV-B NET PRODUCT REVENUE GUIDANCE FOR
FULL
YEAR 2023 OF BETWEEN $165-$185 MILLION
* QTRLY LOSS PER SHARE $0.19
* Q1 EARNINGS PER SHARE VIEW $-0.13, REVENUE VIEW $38.6
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nPnDB8h0a
Further company coverage: DVAX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Dynavax Technologies
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
OneSpaWorld jumps as co poised to join S&P SmallCap index
Sanofi targets high single digit sales growth in 2026, plans share buyback (updated)
Focus: Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality